| Title |
Antimitotic drugs in the treatment of cancer
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, November 2015
|
| DOI | 10.1007/s00280-015-2903-8 |
| Pubmed ID | |
| Authors |
Rustelle Janse van Vuuren, Michelle H. Visagie, Anne E. Theron, Annie M. Joubert |
| Abstract |
Cancer is a complex disease since it is adaptive in such a way that it can promote proliferation and invasion by means of an overactive cell cycle and in turn cellular division which is targeted by antimitotic drugs that are highly validated chemotherapy agents. However, antimitotic drug cytotoxicity to non-tumorigenic cells and multiple cancer resistance developed in response to drugs such as taxanes and vinca alkaloids are obstacles faced in both the clinical and basic research field to date. In this review, the classes of antimitotic compounds, their mechanisms of action and cancer cell resistance to chemotherapy and other limitations of current antimitotic compounds are highlighted, as well as the potential of novel 17-β estradiol analogs as cancer treatment. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 326 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | <1% |
| Switzerland | 1 | <1% |
| Unknown | 324 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 61 | 19% |
| Student > Bachelor | 60 | 18% |
| Student > Master | 48 | 15% |
| Student > Postgraduate | 19 | 6% |
| Researcher | 14 | 4% |
| Other | 39 | 12% |
| Unknown | 85 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 77 | 24% |
| Chemistry | 38 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 35 | 11% |
| Agricultural and Biological Sciences | 29 | 9% |
| Medicine and Dentistry | 27 | 8% |
| Other | 25 | 8% |
| Unknown | 95 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 July 2021.
All research outputs
#7,325,024
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#633
of 2,501 outputs
Outputs of similar age
#88,979
of 284,361 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#10
of 31 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 284,361 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.